Handelsavisen
prelaunch
Companies Healthcare GPTH.NS
GP
GPTH.NS NSE (India) Healthcare Facilities & Services

Gpth.Ns

$141,85
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
1,44 %
Op margin
16,3 %
ROE
20,1 %
Net margin
12,3 %
Debt / equity
0,14
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

GPTH.NS operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.

Business. GPTH.NS operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target136,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
136,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
20,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning GPTH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to GPTH.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    GPTH.NS operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    GPTH.NS maintains a conservative capital structure with a debt-to-equity ratio of 0.14, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.06, suggesting a balanced approach to managing short-term obligations. The company's return on equity of 20.14% and return on assets of 12.99% reflect strong profitability relative to its equity and asset base.

    The company's profitability is further underscored by a gross profit margin of 80.64% and an operating margin of 16.29%, both of which are indicative of efficient cost management and pricing power. These metrics align with the industry's preferred focus on gross and operating margins, suggesting that GPTH.NS is performing in line with or above the median for its sector.

    Geographically and segment-wise, the company's revenue concentration is not explicitly detailed in the available data, but the absence of disclosed segment or geographic breakdowns implies a potentially diversified or consolidated business model. This lack of segmentation data limits the ability to assess specific growth drivers or regional vulnerabilities.

    The company's growth trajectory is supported by a positive free cash flow of 190.26 million INR, which provides flexibility for reinvestment or shareholder returns. Analysts have assigned a mean price target of 136.00 INR, with a single buy recommendation, indicating a generally positive outlook for the company's stock.

    Risk factors for GPTH.NS include a medium liquidity risk, as evidenced by a current ratio just above 1, and a note that net cash is negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding.

    Recent events and filings have not been detailed in the provided data, but the company's financial snapshot and analyst estimates suggest a stable and potentially growing business.

    Key takeaways
    • GPTH.NS demonstrates strong profitability with a high return on equity and operating margin.
    • The company's capital structure is conservative, with a low debt-to-equity ratio.
    • Analysts have a generally positive outlook, with a mean price target of 136.00 INR.
    • The company's liquidity position is moderate, with a current ratio of 1.06.
    • There is a low risk of dilution, as indicated by the low dilution score.
    • margin_outlook_rationale: The company's gross and operating margins are strong, indicating efficient operations and pricing power.
    • rd_outlook_rationale: No specific R&D outlook is provided, but the company's profitability suggests ongoing investment in innovation.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $141,85
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $2.48B
    Net cash
    -$353.0M
    Current ratio
    1.1
    Debt / equity
    0.1
    ROA
    13.0%
    ROE
    20.1%
    Cash conversion
    135.0%
    CapEx / revenue
    -12.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    4,60
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-10 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate4,60
    Revenueno estimateno estimate4,7B INR
    Operating incomeno estimateno estimate566,0M INR
    Full-year consensus mean (period as reported by source) · consensus in INR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$136,00 · Median $136,00
    Low $136,00High $136,00
    Operating income · consensus566,0M INR
    EPS surprise
    +32,2 %
    reported vs consensus · beat
    Revenue surprise
    −13,1 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$136,00
    Mean$136,00
    Median$136,00
    High$136,00
    Spot$141,85
    −4.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin16,3 %Above P75
    Net Margin12,3 %Above P75
    ROE20,1 %Best in class
    Capex / Rev-12,3 %Below median
    D/E0,14Above median
    Cash Conv1,35Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • GPTH.NS Market data — financials · 2026-05-28
    • GPT Healthcare Ltd Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    GPTH.NSCanonical
    NSE (India) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage